肝硬化肝癌患者腹腔镜肝切除的手术指征能否扩展
该多中心回顾性研究纳入欧洲七中心403例腹腔镜肝癌切除,比较333例肝硬化与70例非肝硬化患者,并匹配比较100例Child-Pugh A与25例B患者。结果显示两组出血量、并发症及肝特异性并发症无差异,Child-Pugh B围术期结局亦相似;肝硬化组无复发生存更短但总生存相似。ASA评分与中转开腹是大并发症危险因素。
要点
- 肝硬化与非肝硬化肝癌患者腹腔镜肝切除安全性相当。
- Child-Pugh B患者围术期结局与A级相似,指征可考虑扩展。
- ASA评分与中转开腹是大并发症危险因素,而非肝硬化严重程度。
核心结论
- 腹腔镜肝癌切除在肝硬化与非肝硬化患者中安全性相当,晚期肝硬化患者亦可获益。
- 严重合并症与中转开腹应视为并发症危险因素,而非肝硬化严重程度或门脉高压。
研究设计与样本
- 多中心回顾性分析,纳入欧洲七中心403例腹腔镜肝癌切除。
- 比较333例肝硬化与70例非肝硬化患者,并匹配比较100例Child-Pugh A与25例Child-Pugh B患者。
主要发现
- 肝硬化与非肝硬化组出血量250 vs. 250 mL(p 0.465),并发症28.6 vs. 26.4%(p 0.473),肝特异性并发症12.8 vs. 12%(p 0.924)。
- Child-Pugh A与B亚组围术期结局相似,腹水11 vs. 12%(p 0.562),肝衰竭3 vs. 4%(p 0.595)。
- ASA评分(OR 1.76,p 0.034)与中转开腹(OR 2.99,p 0.019)是大并发症危险因素。
- 肝硬化组无复发生存较短(43 vs. 55个月,p 0.034),总生存相似(84 vs. 76.5,p 0.598)。
临床怎么用
- 肝硬化肝癌患者行腹腔镜肝切除时,应重点评估ASA评分与中转开腹风险。
- Child-Pugh B患者不应仅因肝硬化严重程度而排除腹腔镜肝切除。
局限性
- 回顾性多中心设计,Child-Pugh B样本量较小(25例)。
- 匹配比较仅限Child-Pugh A与B,非随机对照。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Evidence on the value of laparoscopic liver resections (LLR) for hepatocellular carcinoma (HCC) and severe cirrhosis is still lacking. The aim of this study is to assess surgical and oncological outcomes of LLR in cirrhotic HCC patients. METHODS: The analysis included 403 LLR for HCC from seven European centres. 333 cirrhotic and 70 non-cirrhotic patients were compared. A matched comparison was performed between 100 Child-Pugh A and 25 Child-Pugh B patients. RESULTS: There was no difference in blood loss (250 vs. 250 mL, p 0.465) and morbidity (28.6 vs. 26.4%, p 0.473) between cirrhotics and non-cirrhotics, and liver-specific complications were similar (12.8 vs. 12%, p 0.924). The sub-analysis revealed similar perioperative outcomes in either Child-Pugh A or B patients. Noteworthy, ascitis (11 vs. 12%, p 0.562) and liver failure (3 vs. 4%, p 0.595) were not different. ASA score (OR 1.76, p 0.034) and conversion (OR 2.99, p 0.019) were risk factors for major morbidity. Despite lower recurrence-free survival in cirrhotics (43 vs. 55 months, p 0.034), overall survival was similar to non-cirrhotic patients (84 vs. 76.5, p 0.598). CONCLUSION: LLR for HCC appear equally safe in cirrhotic and non-cirrhotic patients, and the advantages can be witnessed in those with advanced cirrhosis. Severe comorbidities and conversion should be considered risk factors for complications-rather than the severity of cirrhosis and portal hypertension-when liver resection is performed laparoscopically. Such results may be of great interest to liver surgeons and hepatologists when deciding on the management of HCC within cirrhosis.
引用
- Cipriani F, Fantini C, Ratti F, et al. Laparoscopic liver resections for hepatocellular carcinoma. Can we extend the surgical indication in cirrhotic patients? Surg Endosc. 2017. PMID: 28717870. doi:10.1007/s00464-017-5711-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。